LIFECORE BIOMEDICAL INC DE

For the period ended May 28, 2023. Filed Mar 20, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 20, 2024

LFCR$6.370.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 15. Exhibits and Financial Statement Schedules

The exhibits listed in the accompanying Index of Exhibits are filed or incorporated by reference as part of this report.
(a)	1.	Consolidated Financial Statements of Lifecore Biomedical, Inc.	Page
		Reports of Independent Registered Public Accounting Firm (PCAOB ID: 42)	67
		Consolidated Balance Sheets at May 28, 2023 and May 29, 2022.	69
		Consolidated Statements of Operations for the Years Ended May 28, 2023, May 29, 2022 and May 30, 2021.	70
		Consolidated Statements of Comprehensive Loss for the Years Ended May 28, 2023, May 29, 2022 and May 30, 2021.	71
		Consolidated Statements of Convertible Preferred Stock and Stockholders’ (Deficit) Equity for the Years Ended May 28, 2023, May 29, 2022 and May 30, 2021.	72
		Consolidated Statements of Cash Flows for the Years Ended May 28, 2023, May 29, 2022 and May 30, 2021.	73
		Notes to Consolidated Financial Statements	74
	2.	All schedules provided for in the applicable accounting regulations of the Securities and Exchange Commission have been omitted since they pertain to items which do not appear in the financial statements of Lifecore Biomedical and its subsidiaries or to items which are not significant or to items as to which the required disclosures have been made elsewhere in the financial statements and supplementary notes and such schedules.
	3.	Index of Exhibits	239

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.